ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Streptomyces amazonensis sp. nov. isolated from Madeira river sediments with genomic potential for secondary metabolite production.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Streptomyces is recognized as a source of secondary metabolites (SMs) with applications in medicine, industry, and agriculture. This study presents the description and characterization of a new Streptomyces species, isolated from sediments of the Madeira River in the Brazilian Amazon. Four strains (CPAA MAD 27, CPAA MAD 39, CPAA MAD 42, and CPAA MAD 51) were obtained from sampling sites distributed along the river. The strains were analyzed for morphological, phenotypic, and biochemical characteristics, as well as their potential for SM production using genome mining. Phylogenetic and phylogenomic analyses indicated that Streptomyces murinus is the most closely related species; however, the dDDH value of 55% and ANI of 94%, combined with biochemical analysis, support the proposal of the isolates as a new species, herein named Streptomyces amazonensis. This species exhibits adaptability to diverse environmental conditions, growing across a wide range of pH values (4–11) and temperatures (15–40 °C), with optimal growth at 35 °C and pH 8, and utilizing various carbon sources, including L-arabinose, unlike S. murinus. Genomic analysis revealed 39 to 46 biosynthetic gene clusters (BGCs) per strain, related to polyketides, nonribosomal peptides, and ribosomally synthesized and post-translationally modified peptides (RiPPs). Notably, BGCs showed high similarity to thioligamide (antitumor) and tetracenomycin (antibiotic) metabolites. Additionally, numerous BGCs with matches in the MIBiG database were identified, suggesting genomic potential related to the biosynthesis of molecules of scientific interest. This discovery expands our understanding of Amazonian microbial diversity and offers new prospects for the bioprospecting of natural products, highlighted by the unexplored biosynthetic potential of S. amazonensis for the development of new natural compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.